Information Provided By: 
Fly News Breaks for February 23, 2018
EXAS
Feb 23, 2018 | 07:37 EDT
Canaccord analyst Mark Massaro noted he recently lowered his Q1 estimates on Exact Sciences to highlight tough weather comps year-over-year. The analyst said he underestimated the impact the severe flu season would have on a doctor's ability to see patients for wellness visits when they would prescribe Cologuard. Although Massaro expects the stock to be down on the guidance, he does not expect it to persist past the flu season. Massaro reiterated his Buy rating and lowered his price target to $55 from $60 on Exact Sciences shares.
News For EXAS From the Last 2 Days
There are no results for your query EXAS
